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Abstract Inhaled corticosteroids (ICS) are the most effec-
tive anti-inflammatory drugs for the treatment of persistent
asthma in children. Treatment with ICS decreases asthma
mortality and morbidity, reduces symptoms, improves lung
function, reduces bronchial hyperresponsiveness and
reduces the number of exacerbations. The efficacy of ICS
in preschool wheezing is controversial. A recent task force
from the European Respiratory Society on preschool
wheeze defined two different phenotypes: episodic viral
wheeze, wheeze that occurs only during respiratory viral
infections, and multiple-trigger wheeze, where wheeze also
occurs in between viral episodes. Treatment with ICS
appears to be more efficacious in the latter phenotype.
Small particle ICS may offer a potential benefit in
preschool children because of the favourable spray charac-
teristics. However, the efficacy of small particle ICS in
preschool children has not yet been evaluated in prospec-
tive clinical trials. The use of ICS in school children with
asthma is safe with regard to systemic side effects on the
hypothalamic–pituitary–adrenal axis, growth and bone
metabolism, when used in low to medium doses. Although
safety data in wheezing preschoolers is limited, the data are
reassuring. Also for this age group, adverse events tend to
be minimal when the ICS is used in appropriate doses.
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Introduction
Inhaled corticosteroids (ICS) are the cornerstone of asthma
treatment in adults and children. They remain the most
effective anti-inflammatory drugs for the treatment of
persistent asthma. Since their introduction in the early
1970s, no other equally effective drug for asthma treatment
has become available, and this will probably remain so for
the foreseeable future. Treatment with ICS has decreased
asthma mortality and morbidity [61]. In addition, treatment
with ICS reduces symptoms, improves lung function,
reduces the degree of bronchial hyperresponsiveness
(BHR) and reduces the number of exacerbations [1–3].
ICS treatment improves the burden of asthma by decreasing
the number of nocturnal awakenings due to respiratory
symptoms, by reducing school absence and, especially
valuable for children, by helping to enable participation in
sports and other social activities [60].
The goal of asthma therapy for children is to achieve
asthma control by optimising lung function, reducing day
and night time symptoms, reducing limitations in daytime
activities and the need for reliever treatment and by
reducing asthma exacerbations [27]. However, especially
in children, it is of importance to achieve control with a
minimum of side effects of medication.
Guidelines from all countries advocate the use of ICS for
the treatment of persistent asthma. Due to the efficacy of
ICS as a class, low- to medium-dose ICS treatment
outweighs the potential risks of adverse effects [53]. Recent
Global Initiative for Asthma Guidelines recommend low-
dose ICS (low-to-medium dose 100–200 μg beclometha-
sone dipropionate (BDP) equivalent twice daily or 125–
250 μg fluticason twice daily) therapy when asthma
symptoms requiring a short-acting beta2-agonist occur more
than once per week (but less than daily; step 2) and as
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baseline therapy with various adjunctive therapies for more
severe disease (steps 3 and 4) [27]. In children 5 years of
age or younger, low-dose ICS is advocated in partly
controlled asthma, with a doubling of the dose for those
with uncontrolled asthma or asthma that is partly controlled
on a low-dose of ICS (see Fig. 1).
ICS therapy for asthma, especially for children, has
changed substantially since the introduction of the first ICS,
BDP, in the early 1970s, followed soon thereafter by
budesonide (BUD). Over the last two decades, a number of
novel ICS, such as fluticasone propionate (FP), as well as
the small particle ICS ultrafine hydrofluoroalkane (HFA)-
BDP and ciclesonide, have entered the market. In addition
to improvements in the ICS molecules available for the
treatment of asthma, our understanding of the importance of
the deposition characteristics of these drugs in determining
safety and efficacy has increased. Finally, there have been
significant advances in inhaler technology, and this too can
impact the effectiveness of an ICS. The purpose of this
review, therefore, is to provide an updated overview of
relevant studies in children of school age as well as in
preschool children with respect to the efficacy, safety and
lung delivery of ICS.
History
In 1936, cortisone, initially called compound E, was for the
first time extracted from the renal cortex by Edward Kendal
at the Mayo Clinic. In 1950, the first report on successful
use of cortisone in asthma was published, followed soon
thereafter by a confirmatory clinical trial [16,58]. Despite
its apparent efficacy, it became obvious that the adverse
effects following long-term treatment were substantial.
Hypertension, diabetes mellitus, osteoporosis, obesity,
facial mooning, acne, skin thinning and bruising, the
development of glaucoma and, especially in children,
growth retardation were some of the severe complications
of this relatively new treatment option. Search for safer
compounds and safer modes of administration of cortico-
steroids led to the introduction of inhaled BDP in the
1970s, which, based on evidence from clinical trials, was
administered four times per day, following initial approval.
Subsequently, Willey et al. showed that twice daily
administration of the new corticosteroid, BUD (200 μg
twice daily), was as effective as four times daily therapy
[74]. Based on these data, as well as patient preference,
twice daily dosing became the standard regimen for all ICS
with the exception of ciclesonide and budesonide in mild
asthma, which can be administered by inhalation once
daily. However, it is important to note that ciclesonide is
not approved for once daily use in some countries such as
the USA.
Inhaled corticosteroids also became the standard of care
for the treatment of asthma in children after it had been
convincingly demonstrated that treatment of the underlying
airway inflammatory processes provided overall asthma
control that was far superior to bronchodilator treatment
alone. In children aged 7–16 years, Van Essen-Zandvliet et
al. [67] showed that the effects of chronic treatment with
BUD (100 μg administered three times per day for
22 months) was far superior to chronic treatment with the
short acting β2 adrenergic drug, salbutamol (200 μg
administered three times per day), with respect to asthma
symptoms, lung function, degree of BHR and frequency of
exacerbations. Eight years later, these results were con-
firmed in a much larger population of school children (aged
5–12 year) in the USA with mild to moderate persistent
asthma who received 200 μg budesonide, 8 mg nedocromil,
or placebo twice daily for 4–6 years [64]. The results of
these and other paediatric asthma studies provide a solid
foundation for our current understanding of ICS and their
role in the treatment of paediatric asthma, and one may
conclude that inhaled corticosteroid treatment is very
effective in school-aged children.
Despite the introduction of other classes of medications
for children with asthma in the last decades, ICSs continue
to be the recommended first-line maintenance therapy for
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paediatric asthma patients in numerous national and
international asthma treatment guidelines. For example,
inhaled, long-acting beta2-agonists (LABA) were intro-
duced approximately 20 years ago. Early studies with
LABAs in children showed little or no benefit when these
agents were added to a maintenance regimen that included
an ICS [51,70]. A more recent systematic review in adults
and children [54] showed that the addition of LABA to an
ICS in patients who are symptomatic on low to high doses
of ICS reduces the rate of exacerbations requiring systemic
corticosteroids, improves lung function and asthma symp-
toms and reduces the use of rescue short-acting beta2-
agonists. However, when only paediatric studies were
included in the analyses [55], the addition of a LABA to
an ICS was not associated with a significant reduction in
the rate of exacerbations requiring systemic corticosteroids
but was associated with a significant improvement in lung
function compared with an ICS alone. Similarly, compared
with a double dose of ICS, the combination of a LABA and
a lower dose of ICS did not significantly decrease the risk
of exacerbations requiring oral corticosteroids, but it did
result in significantly greater improvements in peak
expiratory flow and caused significantly less growth
impairment [55].
A major new class of asthma treatments introduced
within the past 15 years belongs to the class of agents
referred to as leukotriene-modifying drugs. As a class, these
agents did not have a major impact on treatment outcomes
in paediatric asthma. A dose of 400 μg/day of BDP or
equivalent ICS appeared to be more effective than the usual
approved doses of anti-leukotriene agents [23]. In addition,
the use of anti-leukotrienes as add-on therapy to ICS leads,
at most, to modest improvements in lung function, and
overall asthma control often deteriorates when the ICS is
tapered or discontinued [22].
Despite the introduction of other classes of asthma
medication, ICS remain the most important anti-asthma
therapy in school children with asthma.
Inhaled corticosteroids in preschool children
Population studies have shown that one in three children
will have at least one episode of wheezing before they
reach their third birthday, rising to almost one in two (50%)
by age 6 [30,49]. Unfortunately, the ability to predict who
among these children will have transient versus persistent
problems is poor. As such, epidemiological data, such as
these, has limited clinical applicability. In this regard,
prospective studies in which subjects were also phenotyped
using a number of different clinical measures (e.g., lung
function, BAL, etc.) showed considerable overlap between
these groups [13]. Therefore, at present, there are no
diagnostic tools that can reliably predict the development
of asthma among wheezy infants.
Noisy breathing is common among infants. It is
important to note that it is difficult for parents to recognise
wheezing, and accurately identifying wheezing by medical
history is virtually impossible, as the term is used by
parents and doctors to describe a variety of symptoms [15].
Children with physician-confirmed wheezing have higher
airway resistance than children with parent-reported wheeze
[47]. It may be that physician-confirmed wheezing can
become important as a predictor for the development of
asthma at older age. We observed that preschool children
with an increased specific IgE and who also wheezed had a
substantially increased chance of developing asthma by
the time they reached school age [25]. Unfortunately, in
this study, wheezing was not reported by a physician.
Devulapalli et al. demonstrated that a high severity score
of obstructive airways disease by 2 years of age is a strong
risk factor for, and may predict, current asthma at 10 years
of age [19]. Bronchial biopsies obtained from infants with
confirmed wheezing have shown increased thickness of
the reticular basal membrane and significantly greater
eosinophilic inflammation compared with samples from
children with parent-reported wheezing or control subjects
[59].
Early identification of asthma is mandatory in school
children since early treatment in this age group can prevent
exacerbations and deterioration of lung function. However,
in preschool children, no such data are available. Recent
early intervention studies with ICS in young children aimed
at the prevention of asthma have shown no beneficial
results with respect to the development of asthma
[11,29,52], and the results of therapeutic studies are
conflicting.
Episodic viral wheeze [13]
Episodic viral wheeze has been defined recently by a
European Respiratory Society task force to describe
children who wheeze intermittently and are well between
episodes. The efficacy of ICS in the treatment for episodic
viral wheeze in preschool children is controversial. The
majority of asthma exacerbations in school-aged children
are associated with viral infections [35], and this also holds
true for the majority of wheezing episodes in preschool
children [77]. Intermittent versus daily ICS treatment in
children was reviewed by the Cochrane Airways Group
[50]. Studies in children up to 17 years of age were
included, but the review also contained studies conducted
in preschool children. This review showed that children
benefited from intermittent use of high-dose ICS (1,600–
3,200 μg/day BDP or BUD) as evidenced by a reduction in
the severity of symptoms. There was also a trend for
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reduced requirements of oral corticosteroids. More recently,
a controlled, randomised, double-blind clinical trial of
750 μg FP versus placebo twice daily in 129 children
who were 1–6 year of age with recurrent virus-induced
wheezing showed a reduction in the use of rescue oral
corticosteroids in the FP-treated patients [24]. However,
treatment with FP was associated with a smaller gain in
height and weight. Among preschool children, no benefit
was shown for continuous low-dose ICS treatment
(400 μg/day BUD) with respect to a reduction in the
number or the severity of wheezing episodes [75].
Finally, a double-blind, placebo-controlled, randomised
interventional study, primarily designed to assess whether
or not treatment with intermittent courses of inhaled
budesonide (400 μg/day) versus placebo for 2 weeks
during wheezing episodes could delay progression to
persistent wheezing, did not show any benefit of ICS
during the first 3 years of life [11].
Maintenance treatment with ICS in episodic viral
wheeze in low-to-medium dosage seems not beneficial.
Intermittent treatment with high-dose ICS during wheezing
episodes has some beneficial effects but increases the risk
of systemic side effects. An alternative possibility for this
phenotype is treatment with montelukast, which reduced
the rate of wheezing episodes in 549 preschool children
with episodic viral wheeze by 32% compared to placebo
[12].
Multiple-trigger wheeze [13]
Multiple-trigger wheeze has been defined recently by a
European Respiratory Society task force to describe
children who wheeze both during and outside discrete
episodes. The treatment of preschool children with
multiple-trigger wheeze with ICS appears to be more
successful than that of children with episodic viral wheeze.
Children with multiple-trigger wheeze often develop symp-
toms after crying, laughter or exercise. Based on these
findings, many believe that multiple-trigger wheeze resem-
bles allergic asthma, but there is little direct evidence to
support this. It remains unknown whether the histopathol-
ogy of the airways from children with multiple-trigger
wheeze resembles that of allergic asthma. However, a
proportion of preschoolers with persistent wheeze do
develop asthma in later life [49,78].
Kaditis et al. [37] and Castro-Rodriguez et al. [17]
reviewed the literature on the efficacy of ICS in recurrent
wheezing preschool children. Based on these systematic
reviews, as well as a number of randomised, double-blind,
placebo-controlled clinical trials published after this review
was completed, it is concluded that continuous treatment
with ICS decreases the number of days with symptoms
among children with persistent wheezing, without prevent-
ing the need for hospitalisation [14] and had less wheezing/
asthma exacerbations and improved their symptoms and
lung function, respectively [17].
There is solid evidence that maintenance treatment with
a low-to moderate dose of ICS decreases the number of
days with asthma symptoms in children with multiple-
trigger wheeze. However, Kaditis et al. [37] questioned
whether the relative benefit of continuous treatment with
ICS (approximately 5% fewer symptom-free days versus
placebo) is clinically significant and outweighs the possible
side effects. Montelukast improved symptoms and achieved
a 30% reduction in exacerbations in 689 preschool children
with multiple-trigger wheeze [41], but head-to-head com-
parisons with an inhaled corticosteroid are not available in
the literature [7,13] (Table 1).
Newer, small particle ICS, such as ultrafine HFA-BDP
aerosol (QVAR) and ciclesonide, may offer a potential
benefit in preschool children. This resulted in a recommen-
dation in the revised Dutch Paediatric Asthma Guidelines
2007 to treat children under 6 years with a small particle
ICS [32]. This recommendation is primarily based on a
Table 1 Characteristics of episodic viral wheeze and of multiple-trigger wheeze
Episodic viral wheeze Multiple-trigger wheeze
Definition Wheezing during discrete time periods, often in
association with clinical evidence of a viral cold
Wheezing that shows discrete exacerbations
but also symptoms between episodes
Triggers Viral infections Viral infections, tobacco smoke, allergen
exposure, mist exposure, crying, exercise
Possible underlying factors Pre-existent impaired lung function,
tobacco smoke exposure, prematurity, atopy
Eosinophilic inflammation?
Continues treatment with ICS Little or no benefit Significant fewer days with symptoms
Treatment with montelukast Moderate benefit Moderate reduction in exacerbations
Long-term outcome Declines over time (<6 year), can continue as
episodic viral wheeze into school age, can
change in multiple-trigger wheeze
Can continue as asthma into adulthood
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model-deposition study that is outlined below. The average
particle size is smaller [median mass aerodynamic diameter
(MMAD) of both compounds is 1.1 μm], the velocity of the
particles leaving the inhaler on actuation is slower, the
duration of the spray is longer and the temperature of the
spray is warmer compared with that of traditional inhalers
[42]. As a result, a softer more gentle spray is produced,
fewer particles impact on the oropharynx and more drug
reaches the lung, particularly the small airways [43]. These
improved delivery characteristics may be particularly
relevant for young children in whom a greater proportion
of airways are classified as small (i.e. <2 mm in diameter)
and airways resistance is low [68].
In adults with asthma, ultrafine HFA-BDP aerosol
provides equivalent asthma control at half the daily dose
of conventional chlorofluorocarbon (CFC)-BDP [18]. Two
clinical studies with ultrafine HFA-BDP were performed in
school children with asthma [62,66]. The first was a 6-
month, open-label, randomised clinical trial that confirmed
that asthma control can be well maintained in children aged
5–11 years when switching from a conventional CFC-BDP
metered dose inhaler (MDI) inhaled via a spacer to ultrafine
HFA-BDP (administered via an Autohaler®) at doses as
low as 100–200 μg/day [62]. A randomised controlled,
double-blind, double-dummy clinical trial in school chil-
dren aged 5–12 years with mild–moderate asthma showed
that ultrafine HFA-BDP MDI and CFC-fluticasone MDI
were equally effective in improving asthma control in
children with mild–moderate asthma at the same daily dose
and that the majority of children in both groups could
reduce their daily dose to as low as 50 μg/day while
maintaining good asthma control [66]. In 2008, a Cochrane
Systemic Review compared ciclesonide with other inhaled
corticosteroids in children and adults with asthma [48]. The
majority of the studies were performed in asthma patients
from 12 to 75 years of age. Three of the studies were
performed in children, aged 6–11, 12–17 and 6–11 years,
respectively [57,71,73]. In 6–11-year-old children, a rand-
omised, double-blind, double-dummy, three-arm, parallel
group study showed that once daily ciclesonide (80 or
160 μg daily) administered via a MDI without a spacer had
a clinical effect similar to that of FP (100 μg twice daily)
administered via a MDI [57]. The two other studies
compared the efficacy of ciclesonide (320 and 160 μg once
daily, respectively) with BUD (800 μg and 400 μg once
daily, respectively). These studies were conducted over a
period of 12 weeks in children with asthma ages 12–17 and
6–11 years, respectively, and the results showed similar
efficacy with ciclesonide and BUD in a 1:2 dose ratio
[71,74].
Unfortunately, the efficacy of small particle inhaled
corticosteroids in preschool children has not yet been
evaluated in prospective clinical trials. This is the reason
that HFA-BDP in The Netherlands is registered from the
age of 5 years and older. This is in contrast with the
recommendation in the revised Dutch Paediatric Asthma
Guidelines 2007 [32]. The only study that suggests that
small particle ICS may have an advantage in very young
children is an infant model study. In an anatomically correct
model of the upper airway of a 9-month-old infant, the
SAINT model [33], lung deposition of CFC-BDP (MMAD
3.5–4.0 μm) and ultrafine HFA-BDP (MMAD, 1.1 μm)
was compared. The SAINT model was connected to a
breathing simulator and a cascade impactor. This study
showed that lung doses for ultrafine HFA-BDP were 25.4–
30.7% over the range of tidal volumes evaluated (50–
200 ml), while the lung doses for CFC-BDP ranged from
6.8% to 2.1% [34]. The deposition of the small particles
was relatively independent of tidal volume, which may be a
theoretical advantage in young children. This study sug-
gests that ultrafine HFA-BDP will be delivered in an
increased lung dose in preschool children compared with
an ICS that has a higher MMAD. However, these data must
be interpreted with the caveat that drug delivery for
individual patients in clinical practice also depends on
other factors such as the inhalation technique and the
cooperation of the child (Table 2).
Adverse effects
Local adverse effects of inhaled corticosteroids, such as
hoarseness as well as oral candidiasis, may cause serious
discomfort in children, although these adverse effects are
less common than in adults.
Due to the well-known adverse effects of systemic
corticosteroids, there is general awareness of the potential
for adverse systemic effects with ICS as well, especially
when they are administered at high doses for extended
periods of time. Adverse systemic effects of ICS have been
reviewed extensively [8,39,40,44,45,56,65]. All corticoste-
roid actions are mediated through the stimulation of
glucocorticosteroid receptors in the cytoplasm of cells
throughout the tissues. However, there is widespread
heterogeneity in both the efficacy as well as the systemic
safety of ICSs among individuals with asthma, even when
using the same doses of ICS. This variability in response is
multifactorial and includes environmental and genetic
factors [39].
Principal methods for reducing systemic activity include
reducing the bioavailability of the ICS from the gastroin-
testinal tract and prolonging residence time of the ICS in
the lung tissue. Improving drug delivery to the lungs by a
better inhalation device may also result in higher systemic
availability of the ICS. Therefore, the efficacy and adverse
effects of an ICS are coupled with the delivery device. The
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ICS molecule can be altered to reduce gastrointestinal
absorption or enhance first-pass metabolism by the liver.
Prolonged residence time in lung tissue can be achieved by
increasing lipophilicity (e.g., mometasone furoate and
fluticasone propionate) or by forming soluble intracellular
esters (e.g., BUD and ciclesonide) [5]. However, all ICSs
delivered to the lung have systemic activity that increases in
a dose-dependent fashion [5].
HPA axis and inhaled corticosteroids
The primary systemic adverse effects of concern following
ICS administration in children are suppression of hypotha-
lamic–pituitary–adrenal (HPA) axis responsiveness, sup-
pression of growth and osteoporosis [5]. Adverse effects of
ICS on the skin (atrophy and bruising) and the eyes
(glaucoma) are, in contrast to adults, uncommon in
children. A number of measures have been used to assess
systemic effects of ICS including effects on HPA axis
function. The presence of exogenous glucocorticosteroids
in the bloodstream will reduce the need for endogenous
cortisol production. Consequently, measures of HPA axis
activity, such as 24-h area under the curve cortisol
concentrations and 24-h urinary free cortisol excretion,
provide sensitive measures of HPA axis suppression.
However, the more sensitive the measure, the more
difficult it is to interpret its clinical significance [39].
Changes in 24-h area under curve for cortisol do not
predict clinically relevant adverse effects [38], such as
Cushing’s disease or adrenal insufficiency/crisis, both of
which are very significant clinical consequences of
exogenous glucocorticoid administration. In children,
clinical manifestations of adrenal suppression as a conse-
quence of the use of ICS are extremely rare [34] and seem
to be related to the administration of very high doses of an
ICS for prolonged periods of time. For example, Drake et
al. described four case reports of adrenal insufficiency
(presenting as hypoglycaemia) reported in children with
asthma who had received high doses (500–1,500 μg/day;
maximum approved dose in children under the age of 12 is
200 μg/day in most countries) of FP for 6 months or
longer [21].
Growth and inhaled corticosteroids
In 1998, an FDA advisory committee reviewed the
available data on growth in children following treatment
with ICS and intranasal corticosteroids. The advisory
committee concluded that growth suppression was a class
effect that occurred with low to medium doses of cortico-
steroids, even when these doses did not produce impair-
ment of other measures of HPA axis function [36].
With the FDA advisory committee findings in mind, it is
important to recognise that like other measures of HPA axis
function, the more sensitive the growth measure, the less
clinically relevant it appears to be. For example, initial
knemometry studies demonstrated a significant and dose-
dependent effect of ICS on lower leg growth velocity
retardation [76], but these effects did not predict effects of
ICS, if any, on the final height of children. The same was
found to be true in year-long studies with the inhaled
corticosteroid, CFC-BDP MDI [20,69]. In two separate,
randomised, double-blind, placebo-controlled clinical tri-
als with 200 μg CFC-BDP twice daily or placebo in
school children ages 6–16 and 7–9 years, respectively,
with asthma, a median growth retardation of approximately
1 cm was observed in the intervention groups relative to
placebo. This small transient reduction in growth velocity
What is known What is new What is uncertain
ICs are the cornerstone of asthma
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does not prevent the
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ICS reduce symptoms, improve lung
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reduces exacerbations in school aged
children
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was also observed in the CAMP study, where 1,041
children from 5 to 12 years of age with mild to moderate
asthma were randomised to 200 μg BUD, 8 mg nedocro-
mil, or placebo twice daily. The children were treated for
4–6 years [64]. However, final height in adulthood among
children following long-term treatment with inhaled
corticosteroids appears to be comparable to that of
children with asthma who were not treated with an ICS
[4]. These studies indicate that low to moderate dosages of
ICS are safe with respect to growth.
Bone metabolism and inhaled corticosteroids
In adults, extensive data are available on the adverse
effects of ICS on bone metabolism, including osteoporo-
sis and fractures. Inhibition of bone metabolism by ICS
could have important long-term consequences, particu-
larly in women where reductions in bone mass may
ultimately result in osteoporosis and an increased incidence
of bone fractures at older ages. There is, however,
continuing debate as to whether a total cumulative dose
or a specific daily dose range is the best predictor of bone
loss.
The adverse effects of ICS on bone mineral density and
bone metabolism in children with asthma are not well
defined, but effects do appear to be dose related. Six
months of high-dose treatment with 1,000 μg of FP in
children aged 5–19 years did not result in a significant
reduction in bone metabolism or bone mineral density [28].
This is in contrast with an earlier study over a period of
1 year that showed a change in bone mineral content in
children aged 5–14 years treated with high doses of BDP or
BUD (range of doses, 400–2,000 μg/day) [6]. Similarly, a
step-down study in children aged 6–10 years who were
treated with FP (1,000 μg/day) for 2 months showed a
reduction in bone metabolism and lower leg growth
velocity, as well as HPA axis suppression [72]. However,
all adverse effects observed in the initial high-dose FP
treatment period disappeared after dose reduction. It is
also important to note that direct measurements on bone,
as well as measures of bone biomarkers, show no
evidence that low to medium doses of ICS effect bone
density [5]. In this regard, the CAMP study [64], where
children aged 5–12 years at study entry were treated for 4–
6 years with 400 μg/day of budesonide DPI, found no
evidence that long-term BUD treatment affected bone
mineral density.
Adverse effects in preschool children
There is limited safety data on ICS in very young
children, but the data that are available are reassuring.
Lødrup Carlsen et al. showed in a randomised, multi-
center, placebo-controlled, parallel group study of chil-
dren ages 12–47 months, who were treated with either
100 μg of FP or placebo twice daily for 12 weeks, that
FP was well tolerated, and the overall adverse event
profile was similar in the two groups [46]. Urinary
cortisol/creatinine ratios were slightly decreased among
FP patients after 12 weeks, but there were no adverse
events linked to HPA-axis suppression in this study.
Another randomised, double-blind, placebo-controlled,
parallel-group trial in infants aged 6–12 months receiving
0.5 or 1.0 mg of BUD as a nebulised suspension, or
placebo, for 12 weeks showed that the safety profile of
BUD suspension was similar to that of placebo, with no
suppressive effects on adrenal function [9]. More recently,
daily treatment with inhaled 250 μg FP (administered as
125 μg via a MDI with a spacer two times daily) for
18 months in children with a mean age 10 months who
had recurrent wheeze and a family history of asthma was
shown to have no adverse effects on the HPA axis or on
linear growth [31]. However, FP treatment was associated
with increases in body weight and body mass index. These
results are consistent with earlier studies in 471 children
aged 1–3 years who received 200 μg FP (administered as
2×50 μg via a MDI with a spacer two times daily) for
52 weeks and 40 children under 2 years of age who were
randomised to either 100 μg or 250 μg of FP (adminsis-
tered as one single puff via a MDI with a spacer two times
daily) or placebo for 6 months [10,63]. Guilbert et al.
conducted a clinical study in 2–3-year-old children who
received FP 200 μg/day (administered as two 50-μg puffs
via an MDI with a spacer two times daily) or placebo for
2 years and showed that there was a mean difference of
−1.1 cm from placebo in height at the end of the 2-year
treatment period [21]. In this same study, a −0.7 cm
difference in height from placebo was observed 1 year
following the cessation of study medication [29]. The
authors questioned, however, whether height would have
become similar in the two groups as the cohort matured.
Finally, in the IFWIN study, children aged 0.5–4.9 years
were randomised to receive 200 μg FP (administered as
100 μg via a MDI with a spacer twice daily) or placebo
[52]. After 6 months, the FP group had a decrease in Z-
score (the height standard deviation scores calculated from
the UK 1990 reference curves). [26,78] At 5 years of age,
both the FP and the placebo groups had similar changes in
Z-scores relative to the pre-treatment Z-scores. All FP-
treated children had received treatment for at least
9 months. The temporary reduction in growth in the FP
group is comparable to the effects observed in school
children with asthma. Together, these data show that with
respect to growth, ICS are well tolerated and have minimal
or no long-term effects on growth when used in appropri-
ate doses.
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Conclusions
Inhaled corticosteroids remain the most effective anti-
inflammatory therapy for the treatment of adults and
school-aged children with asthma. The efficacy of ICS in
preschool children with episodic viral wheeze remains
controversial, while ICS treatment of preschool children
with multiple-trigger wheeze appears to be at least
somewhat effective. However, the effect size in preschool
children with multiple-trigger wheeze is smaller than the
effect size in school-aged children with asthma.
In school children with asthma, small-particle ICSs, such as
ultrafine HFA-BDP and ciclesonide, are as effective as
fluticasone propionate on a microgram for microgram basis,
and at least as effective, at half the dose, as BUD and CFC-
BDP. The small particle ICSs appear to have theoretically a
very favourable benefit/risk ratio in preschool children, but
prospective clinical studies with these ICS in this age group are
needed. ICS are generally well tolerated in both school-aged
and preschool children, and adverse events tend to be minimal
in both age groups when the ICS is used in appropriate doses.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
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